Top 20 biopharmas’ market cap rises 2% in Q3 2024 amid flurry of drug approvals
The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor optimism improved following the interest rate cuts by the US Federal Reserve in September 2024.
What's Your Reaction?